[go: up one dir, main page]

BR0116063A - Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos - Google Patents

Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos

Info

Publication number
BR0116063A
BR0116063A BR0116063-0A BR0116063A BR0116063A BR 0116063 A BR0116063 A BR 0116063A BR 0116063 A BR0116063 A BR 0116063A BR 0116063 A BR0116063 A BR 0116063A
Authority
BR
Brazil
Prior art keywords
heterocyclically
beta amyloid
amyloid production
sulfonamide inhibitors
production
Prior art date
Application number
BR0116063-0A
Other languages
English (en)
Inventor
Anthony Frank Kreft
Derek Cecil Cole
Kevin Roger Woller
Joseph Raymond Stock
George Diamanitis
Dennis Michael Kurbrak
Kristina Martha Kutterer
William Jay Moore
David Scott Casebier
Original Assignee
Wyeth Corp
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22966854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0116063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Arqule Inc filed Critical Wyeth Corp
Publication of BR0116063A publication Critical patent/BR0116063A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES DE SULFONAMIDA HETEROCìCLICA DA PRODUçãO DE BETA AMILóIDE E SEUS USOS". Compostos de Fórmula (I), onde R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, T, W, X, Y e Z são como aqui definidos, são fornecidos, juntamente com sais, hidratos e/ou pró-drogas farmaceuticamente aceitáveis destes. Métodos uso desses compostos para a inibição da produção de beta amilóide e para tratamento de Doença de Alzheimer e síndrome de Down são descritos.
BR0116063-0A 2000-12-13 2001-12-11 Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos BR0116063A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25510500P 2000-12-13 2000-12-13
PCT/US2001/048375 WO2002057252A2 (en) 2000-12-13 2001-12-11 Heterocyclic sulfonamide inhibitors of beta amyloid production

Publications (1)

Publication Number Publication Date
BR0116063A true BR0116063A (pt) 2004-08-03

Family

ID=22966854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116063-0A BR0116063A (pt) 2000-12-13 2001-12-11 Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos

Country Status (28)

Country Link
US (5) US6610734B2 (pt)
EP (1) EP1341779B1 (pt)
JP (2) JP2004517892A (pt)
KR (1) KR100869061B1 (pt)
CN (2) CN1800176A (pt)
AR (1) AR035516A1 (pt)
AT (1) ATE330950T1 (pt)
AU (1) AU2002245123B2 (pt)
BR (1) BR0116063A (pt)
CA (1) CA2436526C (pt)
CY (1) CY1105441T1 (pt)
DE (1) DE60121032T2 (pt)
DK (1) DK1341779T3 (pt)
EA (1) EA009035B1 (pt)
ES (1) ES2267853T3 (pt)
HK (1) HK1059619A1 (pt)
HU (1) HUP0303857A3 (pt)
IL (3) IL156268A0 (pt)
MX (1) MXPA03005255A (pt)
NO (1) NO328885B1 (pt)
NZ (2) NZ526213A (pt)
PL (1) PL365950A1 (pt)
PT (1) PT1341779E (pt)
SG (1) SG128491A1 (pt)
SI (1) SI1341779T1 (pt)
TW (1) TWI235155B (pt)
WO (1) WO2002057252A2 (pt)
ZA (1) ZA200304135B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365196B2 (en) * 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
CN1800176A (zh) 2000-12-13 2006-07-12 惠氏 β淀粉样蛋白产生的杂环磺酰胺类抑制剂
EP1461303A4 (en) * 2001-12-11 2006-07-05 Wyeth Corp PROCESS FOR THE SYNTHESIS OF CHIRAL-PURITY B-AMINO ALCOHOLS
SG143986A1 (en) * 2002-06-11 2008-07-29 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
US7109217B2 (en) 2002-11-12 2006-09-19 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
AU2004251987C1 (en) * 2003-06-30 2010-11-18 Daiichi Sankyo Company, Limited Heterocyclic methyl sulfone derivative
WO2005073198A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
US7569562B2 (en) 2005-01-18 2009-08-04 Elan Pharmaceuticals, Inc. N-substituted heterocyclic sulfonamides
CN101142194B (zh) * 2005-03-14 2012-10-10 顶点制药有限责任公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
GB0602951D0 (en) * 2006-02-14 2006-03-29 Novartis Ag Organic Compounds
BRPI0707742A2 (pt) * 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
MX2008013539A (es) * 2006-04-21 2008-10-29 Wyeth Corp Produccion de intermediarios de amino alcohol quiralmente puros, derivados de los mismos, y usos de los mismos.
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
WO2008059238A1 (en) * 2006-11-17 2008-05-22 Astrazeneca Ab Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer
EP2099741A2 (en) * 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
PE20090824A1 (es) * 2007-07-16 2009-07-24 Wyeth Corp Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas
PE20090445A1 (es) * 2007-07-16 2009-05-18 Wyeth Corp Inhibidores de produccion de beta amiloide
AR067533A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Procesos e inetermediarios para la preparacion de compuestos de sulfonamida heterociclica
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
PA8811701A1 (es) * 2008-01-11 2009-08-26 Wyeth Corp COMPOSICIONES QUE CONTIENEN DERIVADOS DE ARIL SULFONONAMIDA QUE CONTIENEN O-SULFATO Y O-FOSFATO,ÚTILES COMO INHIBIDORES DE ß-AMILOIDE
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
JP5653917B2 (ja) 2008-07-28 2015-01-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経変性疾患の治療のためのｐｋｃ活性化化合物
BR112012014884A2 (pt) 2009-12-17 2016-03-22 Merck Patent Gmbh inibidores de esfingosina quinase
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
EP2945620B1 (en) 2013-01-18 2017-11-22 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
CN104370769B (zh) * 2013-08-14 2017-05-31 重庆博腾制药科技股份有限公司 一种制备羟基金刚烷甘氨酸衍生物的方法
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2017155890A1 (en) * 2016-03-11 2017-09-14 Ohio State Innovation Foundation Novel small molecule antimicrobials
DE202022106287U1 (de) 2022-11-09 2022-11-21 Ahmad Salawi Eine Methode zur Synthese und biologischen Bewertung von neuen Sulfonamid-Analoga

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US656536A (en) * 1899-12-28 1900-08-21 David Fitzgibbons Boiler.
US3376523A (en) * 1966-12-27 1968-04-02 Univ California Transient-suppressing magnetic transmission line
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0510700A3 (en) 1991-04-26 1992-12-16 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) * 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
ZA945719B (en) 1993-08-09 1996-02-01 Lilly Co Eli Identification and use of protease inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
JPH09136878A (ja) * 1995-09-12 1997-05-27 Ono Pharmaceut Co Ltd テトラゾール誘導体
WO1997021690A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
AU1209497A (en) 1995-12-27 1997-07-28 Takeda Chemical Industries Ltd. Oxazole derivatives, their production and use
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
IL129124A0 (en) * 1996-10-11 2000-02-17 Warner Lambert Co Sulfonamide substituted aspartic acid interleukin -1beta converting enzyme inhibitors
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
NZ335157A (en) 1996-11-22 2001-01-26 Elan Pharm Inc N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
DE19650196A1 (de) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
GB9725138D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Thiophenesulfonamide compounds
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
JP2002516904A (ja) * 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
KR20020006626A (ko) 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
WO2001027091A1 (en) * 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
CN1800176A (zh) 2000-12-13 2006-07-12 惠氏 β淀粉样蛋白产生的杂环磺酰胺类抑制剂
EP1461303A4 (en) 2001-12-11 2006-07-05 Wyeth Corp PROCESS FOR THE SYNTHESIS OF CHIRAL-PURITY B-AMINO ALCOHOLS
CA2470111A1 (en) 2001-12-11 2003-06-19 Wyeth Production of chirally pure .alpha.-amino acids and n-sulfonyl .alpha.-amino acids
SG143986A1 (en) * 2002-06-11 2008-07-29 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Also Published As

Publication number Publication date
US20030229127A1 (en) 2003-12-11
CN1800176A (zh) 2006-07-12
NZ526213A (en) 2005-05-27
NO328885B1 (no) 2010-06-07
ZA200304135B (en) 2004-09-03
JP2004517892A (ja) 2004-06-17
NO20032645D0 (no) 2003-06-11
TWI235155B (en) 2005-07-01
CA2436526C (en) 2010-10-19
CY1105441T1 (el) 2010-07-28
US20050196813A1 (en) 2005-09-08
EP1341779A2 (en) 2003-09-10
US20110034513A1 (en) 2011-02-10
US7842718B2 (en) 2010-11-30
PT1341779E (pt) 2006-10-31
JP2010265280A (ja) 2010-11-25
EA200300674A1 (ru) 2004-06-24
IL156268A (en) 2008-04-13
IL156268A0 (en) 2004-01-04
SG128491A1 (en) 2007-01-30
NO20032645L (no) 2003-08-05
ES2267853T3 (es) 2007-03-16
DK1341779T3 (da) 2006-10-30
US7691884B2 (en) 2010-04-06
AR035516A1 (es) 2004-06-02
CN1263750C (zh) 2006-07-12
IL188853A0 (en) 2011-08-01
EA009035B1 (ru) 2007-10-26
KR20040018318A (ko) 2004-03-03
CN1503790A (zh) 2004-06-09
WO2002057252A2 (en) 2002-07-25
MXPA03005255A (es) 2004-10-14
EP1341779B1 (en) 2006-06-21
HUP0303857A2 (hu) 2004-03-29
PL365950A1 (en) 2005-01-24
HUP0303857A3 (en) 2007-07-30
US6610734B2 (en) 2003-08-26
DE60121032T2 (de) 2007-01-11
US6878742B2 (en) 2005-04-12
ATE330950T1 (de) 2006-07-15
US20100022594A1 (en) 2010-01-28
DE60121032D1 (de) 2006-08-03
WO2002057252A3 (en) 2002-12-12
US20020183361A1 (en) 2002-12-05
CA2436526A1 (en) 2002-07-25
KR100869061B1 (ko) 2008-11-17
NZ538100A (en) 2006-07-28
SI1341779T1 (sl) 2006-12-31
AU2002245123B2 (en) 2007-05-24
HK1059619A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0109703A (pt) Derivados de piperazina
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
ECSP055525A (es) Inhibidores de cinasas de tirosina
UY27338A1 (es) Nuevos derivados de ácido sulfónico
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
BRPI0415437A (pt) composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
BR0210507A (pt) Azaindóis
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BR0311767A (pt) Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos
UY28360A1 (es) Nuevos compuestos
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
SE0101932D0 (sv) Pharmaceutical combinations
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BR0210912A (pt) Compostos e composições como inibidores de catepsina
SE9904765D0 (sv) Pharmaceutically-useful compounds
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
UY27034A1 (es) Derivados de pirimidina
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]